title: [Optimization of postoperative medical therapy of infective endocarditis in patients with congenital valvular heart disease].
abstract: The purpose of this study was to evaluate the effectiveness of combined surgical and medical treatment of infective endocarditis in patients with congenital valvular heart disease when included in a regimen of the drug Reamberin. In this regard, the analysis of the effectiveness of a combination regimen of 74 patients with valvular congenital heart diseases complicated with infective endocarditis. Given the indications for surgical correction operative technique features and possible technical difficulties in carrying out such operations, due to the inflammatory changes and tissue destruction, and ways to overcome them. For the correction of metabolic disorders in the postoperative period, 47 patients (main group) was appointed Reamberin: once, intravenous drip 400 ml/day during the first 5 days after surgery. 27 patients (control group) was conducted infusion therapy depending on the severity of the condition according to the classical scheme. In addition to standard clinical and laboratory examination, to assess the effectiveness of Reamberin was investigated catalase activity of CPK in blood serum in the dynamics of observation (1, 3 and 5 days after surgery). It is revealed that surgical approach, used in complex treatment of patients with valvular congenital heart diseases, including reorganization of the cavities of the heart, increasing the frequency of joints and the use of reinforcing strips of synthetic material that prevents the cutting of sutures through the inflamed tissue has achieved good short-and long-term results. Infective endocarditis and destruction of the valvular annulus fibrosus the use of a frame of strips of polytetrafluoroethylene allows you to restore its integrity and to implant a mechanical prosthesis. The inclusion in the regimen of patients with infective endocarditis complicated by cardiac insufficiency in the early postoperative period the drug Reamberin improves the efficiency of treatment by a more rapid restoration of the normal metabolism of cardiomyocytes and accelerates elimination of signs of heart failure.
authors.affiliation: Specialized Hospital for Cardiac Surgery, Nizhny Novgorod.
authors.forename: I S
authors.initials: IS
authors.lastname: Chistyakov
authors.affiliation: Nizhny Novgorod State Medical Academy, Russian Ministry of Health, Nizhny Novgorod.
authors.forename: A P
authors.initials: AP
authors.lastname: Medvedev
authors.affiliation: Nizhny Novgorod State Medical Academy, Russian Ministry of Health, Nizhny Novgorod.
authors.forename: V V
authors.initials: VV
authors.lastname: Pichugin
mesh_terms: D000293:Adolescent; D000328:Adult; D000975:Antioxidants / Q000008:administration & dosage; D003402:Creatine Kinase / Q000097:blood; D004696:Endocarditis / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D006349:Heart Valve Diseases / Q000151:congenital / Q000601:surgery; D019918:Heart Valve Prosthesis Implantation / Q000009:adverse effects / Q000379:methods; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008536:Meglumine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D008659:Metabolic Diseases / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D008875:Middle Aged; D011183:Postoperative Complications / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D013386:Succinates / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D000975:Antioxidants; C549374:Reamberin; D013386:Succinates; D008536:Meglumine; D003402:Creatine Kinase